- Home
- ANIK vs ATOS Comparison
ANIK vs ATOS Comparison
Compare ANIK & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIK
- ATOS
- Stock Information
- Founded
- ANIK 1983
- ATOS 2009
- Country
- ANIK United States
- ATOS United States
- Employees
- ANIK N/A
- ATOS N/A
- Industry
- ANIK Medical/Dental Instruments
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- ANIK Health Care
- ATOS Health Care
- Exchange
- ANIK Nasdaq
- ATOS Nasdaq
- Market Cap
- ANIK 133.1M
- ATOS 106.9M
- IPO Year
- ANIK 1993
- ATOS 2012
- Fundamental
- Price
- ANIK $10.01
- ATOS $0.80
- Analyst Decision
- ANIK Buy
- ATOS Strong Buy
- Analyst Count
- ANIK 1
- ATOS 3
- Target Price
- ANIK $16.00
- ATOS $6.25
- AVG Volume (30 Days)
- ANIK 127.3K
- ATOS 589.7K
- Earning Date
- ANIK 11-05-2025
- ATOS 11-12-2025
- Dividend Yield
- ANIK N/A
- ATOS N/A
- EPS Growth
- ANIK N/A
- ATOS N/A
- EPS
- ANIK N/A
- ATOS N/A
- Revenue
- ANIK $112,806,000.00
- ATOS N/A
- Revenue This Year
- ANIK N/A
- ATOS N/A
- Revenue Next Year
- ANIK $4.57
- ATOS N/A
- P/E Ratio
- ANIK N/A
- ATOS N/A
- Revenue Growth
- ANIK 30.55
- ATOS N/A
- 52 Week Low
- ANIK $7.87
- ATOS $0.55
- 52 Week High
- ANIK $18.37
- ATOS $1.41
- Technical
- Relative Strength Index (RSI)
- ANIK 58.60
- ATOS 36.12
- Support Level
- ANIK $9.41
- ATOS $0.77
- Resistance Level
- ANIK $10.30
- ATOS $0.88
- Average True Range (ATR)
- ANIK 0.38
- ATOS 0.04
- MACD
- ANIK 0.01
- ATOS -0.01
- Stochastic Oscillator
- ANIK 43.70
- ATOS 18.89
About ANIK Anika Therapeutics Inc.
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.